my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
The Boehringer Ingelheim group of companies’ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture.
A new vision for a new world
Value through Innovation: Our vision has helped us build on our strength and make the most of our distinctive character. In a competitive and fast-changing world, the values of products, services and companies are constantly changing. Real customer value today can only be created by constantly finding ways of doing new things well or doing the same things better. Thus the only way for the Boehringer Ingelheim group of companies to create Value is through Innovation.
Lead & Learn: The present phase in our evolution is Lead & Learn. Since 2004, it outlines ways in which Boehringer Ingelheim realises and delivers Value through Innovation. As our corporate culture, Lead & Learn is about all the people at Boehringer Ingelheim and how they work together.
A new vision for the corporate culture: Lead & Learn superseded the concept of Vision & Leadership that was established in 1993 by the Shareholders and the Board of Managing Directors of the Boehringer Ingelheim corporation. The Vision, created for Boehringer Ingelheim worldwide, was built around the corporate vision of Value through Innovation. Since then, our corporate culture always was guided by this vision.
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
Nanobody for Alzheimer's disease moves closer toward phase I clinical trial
Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration sign ... more
Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim
Ablynx announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the ... more
Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of ... more
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed f ... more
The Boehringer Ingelheim group of companies’ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. A ... more
Boehringer Ingelheim Ellas A. E.
Boehringer Ingelheim's production site in Koropi, Greece produces solid forms, supplying European, Asian, African and Australian markets. Solid forms: * granulation * tabletting * tablet coating * capsule filling * blister packaging more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Companies
Netmeeting
